Key Points
- Phreesia General Counsel Allison Hoffman sold 6,662 shares at an average price of $10.08, generating $67,152.96. The sale was conducted under a Rule 10b5-1 plan to cover tax withholding tied to vested equity awards, reducing her stake by 2.44%.
- Phreesia reported quarterly revenue of $129.46 million, up 10.4% year over year and slightly above estimates, but earnings per share of $0.03 fell short of the $0.09 consensus forecast.
- Analyst sentiment remains mixed, with a consensus “Hold” rating and a $14.00 price target; institutional investors own approximately 92.1% of the company’s shares.
Phreesia, Inc. (NYSE:PHR - Get Free Report) General Counsel Allison Hoffman sold 6,662 shares of the company's stock in a transaction on Monday, September 21st. The stock was sold at an average price of $10.08, for a total transaction of $67,152.96. Following the transaction, the general counsel owned 266,574 shares of the company's stock, valued at approximately $2,687,065.92. The trade was a 2.44% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Phreesia Stock Up 0.7%
Shares of NYSE:PHR opened at $10.11 on Wednesday. Phreesia, Inc. has a fifty-two week low of $7.77 and a fifty-two week high of $25.00. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.33. The firm's 50-day simple moving average is $11.14 and its 200-day simple moving average is $10.30. The company has a market cap of $627.22 million, a price-to-earnings ratio of 59.44 and a beta of 0.86.
Phreesia (NYSE:PHR - Get Free Report) last announced its quarterly earnings data on Wednesday, September 2nd. The company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.09 by ($0.06). Phreesia had a net margin of 2.06% and a return on equity of 5.22%. The firm had revenue of $129.46 million during the quarter, compared to analyst estimates of $129.06 million. During the same quarter in the previous year, the business earned $0.01 EPS. Phreesia's revenue for the quarter was up 10.4% on a year-over-year basis. As a group, equities research analysts predict that Phreesia, Inc. will post 0.33 earnings per share for the current year.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the company. Sequoia Financial Advisors LLC purchased a new position in Phreesia in the 2nd quarter valued at about $159,000. Integrated Wealth Concepts LLC raised its position in shares of Phreesia by 37.2% in the second quarter. Integrated Wealth Concepts LLC now owns 14,129 shares of the company's stock valued at $145,000 after buying an additional 3,834 shares during the last quarter. Allworth Financial LP lifted its stake in shares of Phreesia by 78.3% during the second quarter. Allworth Financial LP now owns 5,613 shares of the company's stock valued at $58,000 after buying an additional 2,465 shares during the period. Corient Private Wealth LP lifted its stake in shares of Phreesia by 451.7% during the second quarter. Corient Private Wealth LP now owns 148,290 shares of the company's stock valued at $1,526,000 after buying an additional 121,413 shares during the period. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Phreesia during the second quarter worth approximately $1,038,000. Institutional investors and hedge funds own 92.10% of the company's stock.
Analysts Set New Price Targets
Several research analysts have issued reports on the company. Weiss Ratings cut Phreesia from a "sell (d+)" rating to a "sell (d)" rating in a research report on Friday, September 4th. Citigroup reaffirmed a "market perform" rating on shares of Phreesia in a report on Friday, September 4th. Raymond James Financial downgraded shares of Phreesia from an "outperform" rating to a "market perform" rating in a research report on Tuesday, September 8th. DA Davidson lowered their price target on Phreesia from $14.00 to $13.00 and set a "buy" rating on the stock in a report on Friday, September 4th. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $16.00 price objective on shares of Phreesia in a research note on Thursday, September 3rd. Eight investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Phreesia has a consensus rating of "Hold" and a consensus target price of $14.00.
Read Our Latest Research Report on Phreesia
About Phreesia
(
Get Free Report)
Phreesia, Inc is a healthcare technology company that provides software and services designed to help healthcare organizations manage patient intake and engagement. Its platform digitizes administrative and clinical processes that traditionally rely on paper forms, manual data entry, and separate payment systems.
The company's offerings include digital patient check-in and registration, insurance and demographic information collection, appointment-related communications, electronic forms and consent management, patient surveys, and payment processing.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
